Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Numab Therapeutics AG

Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing
From Numab Therapeutics AG
Via GlobeNewswire
Numab Therapeutics Announces Initiation of Phase 1 Clinical Study of NM32 Program in Patients with Solid Tumors
From Numab Therapeutics AG
Via GlobeNewswire
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
From Numab Therapeutics AG
Via GlobeNewswire
Tickers JNJ
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer
From Numab Therapeutics AG
Via GlobeNewswire
Numab Therapeutics Announces First Patient Dosed in Phase 1 Multiple Ascending Dose (MAD) Study of NM26 for Moderate to Severe Atopic Dermatitis
From Numab Therapeutics AG
Via Business Wire
Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program
From Numab Therapeutics AG
Via Business Wire
Numab Therapeutics and Ono Pharmaceutical Enter Development and License Agreement for Multispecific Antibody Candidate Involving Novel Immuno-Oncology Target
From Numab Therapeutics AG
Via Business Wire
Numab and 3SBio’s Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28
From Numab Therapeutics AG
Via Business Wire
Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing
From Numab Therapeutics AG
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.